It was reported that NK-resistant feature of mixed lineage leukemia (MLL)-rearranged leukemia could be overcome by anti-CD19 antibody and anti-CD33 antibody-induced ADCC, and the effects could be further amplified with pan-MHC-I antibodies, suggesting the utilization of a triple immunotherapy approach, including KIR-mismatched NK cell transfer, antibodies against tumor-associated antigens and inhibitory KIR blockade, for the treatment of MLL-rearranged leukemia [152]. This evidence concerns the gene KMT2A and leukemia.